Atea Pharmaceuticals, Inc. – NASDAQ:AVIR
Atea Pharmaceuticals stock price today
Atea Pharmaceuticals stock price monthly change
Atea Pharmaceuticals stock price quarterly change
Atea Pharmaceuticals stock price yearly change
Atea Pharmaceuticals key metrics
Market Cap | 274.92M |
Enterprise value | 102.00M |
P/E | -2.5 |
EV/Sales | N/A |
EV/EBITDA | -0.94 |
Price/Sales | N/A |
Price/Book | 0.44 |
PEG ratio | N/A |
EPS | -1.96 |
Revenue | N/A |
EBITDA | -191.98M |
Income | -163.65M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAtea Pharmaceuticals stock price history
Atea Pharmaceuticals stock forecast
Atea Pharmaceuticals financial statements
| Jun 2023 | 0 | -28.18M | |
|---|---|---|---|
| Sep 2023 | 0 | -33.14M | |
| Dec 2023 | 0 | -39.16M | |
| Mar 2024 | 0 | -63.16M |
| Sep 2025 | 0 | -67.09M | |
|---|---|---|---|
| Oct 2025 | 0 | -60.41M | |
| Dec 2025 | 1.50M | -63.77M | -4231.44% |
| Mar 2026 | 22.41M | -48.64M | -216.99% |
Analysts Price target
Financials & Ratios estimates
| 2024-02-28 | -0.44 | -0.47 |
|---|
| Jun 2023 | 626028000 | 23.67M | 3.78% |
|---|---|---|---|
| Sep 2023 | 608075000 | 26.34M | 4.33% |
| Dec 2023 | 594968000 | 39.77M | 6.69% |
| Mar 2024 | 553029000 | 48.65M | 8.8% |
| Jun 2023 | -16.12M | 46.56M | 0 |
|---|---|---|---|
| Sep 2023 | -17.59M | -58.51M | 92K |
| Dec 2023 | -21.83M | 27.77M | 0 |
| Mar 2024 | -39.86M | 56.80M | 150K |
Atea Pharmaceuticals alternative data
| Aug 2023 | 73 |
|---|---|
| Sep 2023 | 72 |
| Oct 2023 | 72 |
| Nov 2023 | 72 |
| Dec 2023 | 74 |
| Jan 2024 | 74 |
| Feb 2024 | 74 |
| Mar 2024 | 75 |
| Apr 2024 | 75 |
| May 2024 | 75 |
| Jun 2024 | 74 |
| Jul 2024 | 74 |
Atea Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 126948 |
| Jun 2024 | 0 | 18550 |
| Sep 2024 | 0 | 57969 |
| Dec 2024 | 0 | 359606 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BERGER FRANKLIN M director | Common Stock | 359,606 | $2.85 | $1,023,439 | ||
Sale | SOMMADOSSI JEAN-PIERRE director, officer.. | Common Stock | 1,841 | $4 | $7,368 | ||
Sale | SOMMADOSSI JEAN-PIERRE director, officer.. | Common Stock | 22,187 | $4.03 | $89,480 | ||
Sale | SOMMADOSSI JEAN-PIERRE director, officer.. | Common Stock | 33,941 | $4.05 | $137,325 | ||
Sale | POLSKY BRUCE director | Common Stock | 17,544 | $3.49 | $61,141 | ||
Option | MURPHY POLLY A. director | Common Stock | 33,150 | N/A | N/A | ||
Option | POLSKY BRUCE director | Common Stock | 33,150 | N/A | N/A | ||
Option | MURPHY POLLY A. director | Restricted Stock Units | 33,150 | N/A | N/A | ||
Option | ADAMS JEROME M. director | Restricted Stock Units | 33,150 | N/A | N/A | ||
Option | LUCIDI BRUNO director | Common Stock | 33,150 | N/A | N/A |
| Patent |
|---|
Application BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTI- TUTED PURINE NUCLEOTIDES FOR HCV TREATMENT Filling date: 3 May 2021 Issue date: 25 Aug 2022 |
Application Filling date: 3 May 2021 Issue date: 9 Sep 2021 |
Application Filling date: 10 Nov 2020 Issue date: 9 Sep 2021 |
Application Filling date: 10 Dec 2020 Issue date: 25 Mar 2021 |
Grant Filling date: 5 Mar 2019 Issue date: 16 Mar 2021 |
Grant Filling date: 18 Nov 2019 Issue date: 2 Feb 2021 |
Application Filling date: 7 Oct 2020 Issue date: 21 Jan 2021 |
Grant Filling date: 1 Jul 2020 Issue date: 19 Jan 2021 |
Application Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTI- TUTED PURINE NUCLEOTIDES FOR HCV TREATMENT Filling date: 22 Sep 2020 Issue date: 14 Jan 2021 |
Grant Filling date: 10 Sep 2020 Issue date: 29 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Atea Pharmaceuticals stock today?
One share of Atea Pharmaceuticals stock can currently be purchased for approximately $3.49.
-
When is Atea Pharmaceuticals's next earnings date?
Unfortunately, Atea Pharmaceuticals's (AVIR) next earnings date is currently unknown.
-
Does Atea Pharmaceuticals pay dividends?
No, Atea Pharmaceuticals does not pay dividends.
-
How much money does Atea Pharmaceuticals make?
Atea Pharmaceuticals has a market capitalization of 274.92M. Atea Pharmaceuticals made a loss 135.96M US dollars in net income (profit) last year or -$0.47 on an earnings per share basis.
-
What is Atea Pharmaceuticals's stock symbol?
Atea Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AVIR".
-
What is Atea Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Atea Pharmaceuticals?
Shares of Atea Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Atea Pharmaceuticals's key executives?
Atea Pharmaceuticals's management team includes the following people:
- Dr. Jean-Pierre Sommadossi Ph.D. Founder, Chairman, Chief Executive Officer & Pres(age: 69, pay: $902,990)
- Dr. Janet M.J. Hammond Chief Devel. Officer(age: 65, pay: $728,320)
- Dr. Maria Arantxa Horga M.D. Chief Medical Officer(age: 57, pay: $367,560)
-
Is Atea Pharmaceuticals founder-led company?
Yes, Atea Pharmaceuticals is a company led by its founder Dr. Jean-Pierre Sommadossi Ph.D..
-
How many employees does Atea Pharmaceuticals have?
As Jul 2024, Atea Pharmaceuticals employs 74 workers, which is 1% less then previous quarter.
-
When Atea Pharmaceuticals went public?
Atea Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 30 Oct 2020.
-
What is Atea Pharmaceuticals's official website?
The official website for Atea Pharmaceuticals is ateapharma.com.
-
Where are Atea Pharmaceuticals's headquarters?
Atea Pharmaceuticals is headquartered at 125 Summer Street, Boston, MA.
-
How can i contact Atea Pharmaceuticals?
Atea Pharmaceuticals's mailing address is 125 Summer Street, Boston, MA and company can be reached via phone at 857 284 8891.
Atea Pharmaceuticals company profile:
Atea Pharmaceuticals, Inc.
ateapharma.comNASDAQ
75
Biotechnology
Healthcare
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Boston, MA 02110
CIK: 0001593899
ISIN: US04683R1068
CUSIP: 04683R106
